Impact of a Novel Immune Modulating Dietary Supplement on House Dust Mite Induced Allergic Rhinoconjunctivitis

Exclusion Criteria

• •Current or previous treatment with allergy vaccination within the last two years.
• •Concomitant (or newly developing during study period) severe disease interfering with allergy testing
• •Co-medication interfering with allergy testing for other diseases, e.g. immunosuppressants, oral and/or nasal corticosteroids, chromones and pregnancy
• •Clinically relevant co-sensitization to early blossoming tree pollen allergens, and cat allergens
• •Patient with FEV1 \< 80% of predicted value prior to exposure
• •Patients with severe asthma and / or with a history of uncontrolled asthmatic attacks in the last three months before the selection process
• •Patients with an upper intestinal tract disease, where the local examiner believes that taking the dietary supplement could pose a risk to the patient
• •History of serious chronic medical conditions and/or any disease where, in the opinion of the site investigator, participation in the trial would pose a risk for the patient
• •Treatment prior to study visits and during the whole study time with:
• •* systemic corticosteroids within three weeks (21 days)
• •* topical nasal corticosteroids within two weeks (14 days)
• •* chromones within 7 days
• •* antihistamines within 72 hours before visit 1
• •* antibiotics within 3 months before visit 1 and during the whole study
• •* anti-allergic drugs during the whole study time.